Every story and comment from the Hacker News API, in a layout borrowed from 2001.
A comment on Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms. Parent comment
https://youtu.be/Xu1FMCxoEFc?t=5928
99:33 But one of the things that came up
99:35 and is a fundamental question that I had,
99:37 that I think probably many of you are asking,
99:38 is does the experience that one has on these compounds
99:43 make a difference for whether or not somebody gains relief
99:46 from depression, from these psilocybin journeys or not?
99:50 In other words, does it matter what they talk about?
99:52 Does it matter what they think about?
99:53 Does it matter if they have a good trip or a bad trip?
99:56 And I don't want to hold you in too much suspense,
99:58 I'll let Matthew provide the more thorough answer.
100:00 But what's really interesting
100:02 is there are some common themes to psilocybin administration
100:08 and experience that lead to relief from depressive symptoms,
100:11 but they are subjectively very varied,
100:17 meaning that whether or not people feel
100:20 they had a good experience or a bad experience,
100:22 whether or not people thought about their parents
100:24 or thought about the color of the ceiling,
100:27 doesn't seem to have too much of an impact
100:30 on whether or not they receive relief
100:32 during these studies in these clinical studies.
100:37 It seems like different people can have
100:38 lots of different experiences and still receive benefit.
100:42 And that points to something deeper.
100:45 It points to the fact that these drugs,
100:48 which is really what they are,
100:49 are rewiring neural circuitry in a common way
100:53 despite a diversity of experience while on the drug.
100:57 And that itself is really interesting.
100:58 And it takes us back to a place that we've been before
101:01 in this discussion, which is layer five of the cortex.
101:04 This area that ketamine seems to impact as well
101:06 by generating rhythms of the,
101:08 I mentioned one to three Hertz activity
101:10 in layer five of certain areas of the cortex.
There are no comments on this comment yet.
https://youtu.be/Xu1FMCxoEFc?t=5928
99:33 But one of the things that came up
99:35 and is a fundamental question that I had,
99:37 that I think probably many of you are asking,
99:38 is does the experience that one has on these compounds
99:43 make a difference for whether or not somebody gains relief
99:46 from depression, from these psilocybin journeys or not?
99:50 In other words, does it matter what they talk about?
99:52 Does it matter what they think about?
99:53 Does it matter if they have a good trip or a bad trip?
99:56 And I don't want to hold you in too much suspense,
99:58 I'll let Matthew provide the more thorough answer.
100:00 But what's really interesting
100:02 is there are some common themes to psilocybin administration
100:08 and experience that lead to relief from depressive symptoms,
100:11 but they are subjectively very varied,
100:17 meaning that whether or not people feel
100:20 they had a good experience or a bad experience,
100:22 whether or not people thought about their parents
100:24 or thought about the color of the ceiling,
100:27 doesn't seem to have too much of an impact
100:30 on whether or not they receive relief
100:32 during these studies in these clinical studies.
100:37 It seems like different people can have
100:38 lots of different experiences and still receive benefit.
100:42 And that points to something deeper.
100:45 It points to the fact that these drugs,
100:48 which is really what they are,
100:49 are rewiring neural circuitry in a common way
100:53 despite a diversity of experience while on the drug.
100:57 And that itself is really interesting.
100:58 And it takes us back to a place that we've been before
101:01 in this discussion, which is layer five of the cortex.
101:04 This area that ketamine seems to impact as well
101:06 by generating rhythms of the,
101:08 I mentioned one to three Hertz activity
101:10 in layer five of certain areas of the cortex.